Leiden, The Netherlands, 8 July 2002 - Dutch antibody and vaccine company Crucell N.V. (NASDAQ, Euronext CRXL) emphasises, contrary to interpretations that could be drawn from recent Dow Jones coverage, that it has not changed its profit outlook.

 

Crucell reiterates earlier outlook statements as announced in February 2002 with the publication of the 2001 results.

 

The company is expected to reach profitability once products are brought to market by licensees using its technology.

 

An exact date is not provided, since launching a product depends on several factors, among which are progress of clinical trials and FDA approval.

Crucell will publish its Q2 results on Monday July 15, 2002.

 

About Crucell

Crucell discovers and develops biopharmaceuticals that use the human immune system to combat cancers, infectious diseases and other conditions.  Crucell's patented technology platforms, MAbstractTM, AdVacTM, and PER.C6TM, allow the discovery, development and production of antibodies and vaccines.  Crucell offers its platforms to the pharmaceutical and biotechnology industry as well as using them to create its own product pipeline.  Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine, and Centocor, a Johnson & Johnson company, for the CD46 antibody for treatment of various types of cancer.  In addition, Crucell has over 20 licensees for its PER.C6TM technology.  These include Novartis, GSK, Aventis and Schering AG.  With headquarters based in Leiden, The Netherlands, the company currently employs 200 people. Crucell is listed on Euronext and NASDAQ (ticker symbol CRXL).  For more information visit www.crucell.com.

 

Please click on the link to view formatted release: